WASHINGTON DC—Laboratory evidence that giving patients intermittent rather than continuous treatment with cancer drugs could help them overcome drug resistance in cancers such as melanoma was presented at the American Association for Cancer Research 2013 meeting. Dr Darrin Stuart from the Novartis Institutes for Biomedical Research in Emeryville, California, presented research findings on mice treated with vemurafenib. He told Peter Goodwin why he thought this should prompt clinicians to look carefully at drug scheduling and consider intermittent therapy as a means of overcoming resistance in patients with cancer.
You may also like...
Audio Journal of Oncology in Advance – April 1st, 2007 – reporting From: Journal of Clinical Oncology, January 20th, 2007 & December 20, 2006 2 Apr, 2007 PSA-membrane antibody conjugate shows promise for treating metastatic castration-resistant, taxane-refractory prostate cancer 6 Feb, 2014 Niraparib Quadruples Progression Free Survival in Platinum-Sensitive Ovarian Cancer 21 Oct, 2016 Chronic Lymphocytic Leukemia After Fludarabine Failure 26 Feb, 2008
- Previous story Blood test reliably detects cancer mutations in gastrointestinal stromal tumour
- Next story BRCA-deficient cancers respond to combination of two experimental drugs
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014